Univercells presents its revolutionary biomanufacturing platform: Nevoline system

On Friday January 11th 2019, Univercells presented its revolutionary biomanufacturing platform - the Nevoline system. A facility designed with 4 NevoLine is able to produce 50M doses of polio vaccines at less than $0.30/dose.

In December 2016, a consortium led by Belgium biomanufacturing technology firm Univercells received a $12 million (€10.4 million) grant from the Bill & Melinda Gates Foundation to develop a low-cost vaccine manufacturing platform. The consortium also involves Batavia Biosciences which has developed the polio manufacturing process and Natrix Separations for the purification membrane.

Two years on and a $4 million grant extension has been awarded to Univercells and Batavia Biosciences to scale-up the firm’s NevoLine system for the production of inactivated polio vaccine (sIPV).

“This challenging two-year project aimed at delivering a new manufacturing system to drastically decrease cost, footprint and time to market for vaccine manufacturers, and we are pleased to have met these goals,” said Univercells CEO Hugues Bultot.